Skip to main content
. 2017 Aug 21;40(11):1479–1485. doi: 10.2337/dc17-1011

Table 3.

Sensitivity analyses of AKI in Mount Sinai and Geisinger propensity-matched cohort

Mount Sinai cohort
Geisinger cohort
Unadjusted (95% CI) Adjusted (95% CI) Unadjusted (95% CI) Adjusted (95% CI)
Using AKIKDIGO definition 0.4 (0.2–0.7) 0.4 (0.2–0.7) 0.5 (0.3–0.8) 0.6 (0.4–1.1)
Using AKI ICD codes 0.5 (0.3–0.8) 0.5 (0.3–0.9) 0.43 (0.23–0.79) 0.56 (0.27–1.16)
User/nonusers not missing any covariate data 0.7 (0.3–1.3) 0.7 (0.3–1.4) 0.70 (0.37–1.33) 0.81 (0.40–1.66)
Canagliflozin 0.2 (0.1–0.5) 0.2 (0.1–0.5) 0.54 (0.32–0.93) 0.61 (0.33–1.12)
Dapagliflozin 1.0 (0.5–2.4) 1.1 (0.5–2.7) 0.16 (0.02–1.33) 0.32 (0.02–5.18)
Empagliflozin NA NA 0.50 (0.15–1.66) 0.96 (0.21–4.35)

Results for empagliflozin in Mount Sinai cohort not available (NA) because of small sample size and lack of model convergence.